Immediate oral amiodarone re-challenge following the development of parenteral-induced acute liver toxicity
- Author:
Joseph Offenbacher
1
Author Information
- Publication Type:Letter
- From: World Journal of Emergency Medicine 2021;12(4):321-323
- CountryChina
- Language:English
- Abstract: Amiodarone is a class III antiarrhythmic medication commonly used in the emergency department (ED) and other critical care settings to treat several types of arrhythmias while also serving as a fixture of the Advanced Cardiac Life Support algorithm.[1] Its mechanism of action primarily involves blocking potassium channel currents during myocyte repolarization with additional effects on beta-adrenergic receptors and both sodium and calcium channel blockade.[2] One of amiodarone’s less known complications is the development of acute hepatotoxicity with intravenous (IV) administration.[3] While discontinuation has been recommended, there is limited literature to help guide management when clinical factors warrant its continuation.
